Gerresheimer and Aptar Digital Health have announced a collaboration to develop an integrated solution for managing cancer therapy. The partnership involves connecting Gerresheimer's Gx SensAir on-body drug delivery device with Aptar Digital Health's software-as-a-medical device platform. The aim is to enhance the treatment experience and outcomes for cancer patients by improving the onboarding process, helping patients manage adverse effects, and enabling remote monitoring. The Gx SensAir device is designed for the subcutaneous administration of large molecule biopharmaceuticals, and the integrated solution intends to improve treatment adherence and clinical outcomes.
Daniel Diezi, Vice President Digitalisation & New Business Models at Gerresheimer, emphasised the potential of this collaboration in oncology to lay the groundwork for future expansion into other therapeutic areas. Sai Shankar, President of Aptar Digital Health, expressed excitement about combining expertise in device and software engineering to deliver innovative solutions for patients, healthcare providers, and the healthcare industry. Both companies believe that the integration of subcutaneous injection devices and digital platforms has the potential to enhance the overall patient experience in oncology.
The integrated solution will initially focus on targeted anticancer therapies like PD-1/PDL-1 and CTLA-4, with the possibility of expanding to cover all therapies delivered subcutaneously. This collaboration presents an opportunity for pharmaceutical companies to offer patient-centric solutions, addressing challenges such as treatment interruptions or discontinuations linked to administration issues or adverse effects. Additionally, it supports the transition from intravenous to subcutaneous administration of oncology drugs.
Click here to read the original news story.